Cargando…

Plasma proteomic and metabolomic signatures of B‐ALL patients during CAR‐T cell therapy

Detalles Bibliográficos
Autores principales:	Wu, Jianghua, Tang, Lu, Du, Mengyi, Li, Chenggong, Kou, Haiming, Jiang, Huiwen, Luo, Wenjing, Zhang, Yinqiang, Huang, Zhongpei, Liao, Danying, Xiong, Wei, Mei, Heng, Hu, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026086/ https://www.ncbi.nlm.nih.gov/pubmed/36938989 http://dx.doi.org/10.1002/ctm2.1225

Ejemplares similares

Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis
por: Luo, Wenjing, et al.
Publicado: (2022)

Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia
por: Zhang, Yinqiang, et al.
Publicado: (2022)

IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapy
por: Wang, Xindi, et al.
Publicado: (2023)

P1393: BISPECIFIC CD19/CD37 CAR-T CELLS IN PATIENTS WITH REFRACTORY OR RELAPSED B-CELL LYMPHOMA
por: Luo, Wenjing, et al.
Publicado: (2023)

P1404: IL-10 PLUS THE EASIX SCORE PREDICT BLEEDING EVENTS AFTER ANTI-CD19 CAR T-CELL THERAPY
por: Wang, Xindi, et al.
Publicado: (2023)

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
por: Zhang, Yinqiang, et al.
Publicado: (2023)

Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma
por: Du, Mengyi, et al.
Publicado: (2022)

Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma
por: Li, Chenggong, et al.
Publicado: (2023)

P1442: DYNAMIC LANDSCAPE OF PLASMA PROTEOME AND METABOLOME IN B-ALL PATIENTS DURING CAR-T CELL THERAPY
por: Wu, J., et al.
Publicado: (2022)

Early coagulation tests predict risk stratification and prognosis of COVID-19
por: Luo, Lili, et al.
Publicado: (2020)

T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies
por: Tang, Lu, et al.
Publicado: (2021)

Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy
por: Li, Chenggong, et al.
Publicado: (2020)

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
por: Mei, Heng, et al.
Publicado: (2021)

COVIDomics: The Proteomic and Metabolomic Signatures of COVID-19
por: Costanzo, Michele, et al.
Publicado: (2022)

Convergence of Plasma Metabolomics and Proteomics Analysis to Discover Signatures of High-Grade Serous Ovarian Cancer
por: Ahn, Hee-Sung, et al.
Publicado: (2020)

Plasma metabolomic signatures of breast cancer
por: Xu, Yali, et al.
Publicado: (2023)

Schizophrenia shows a unique metabolomics signature in plasma
por: He, Y, et al.
Publicado: (2012)

Plasma proteomic signature of age in healthy humans
por: Tanaka, Toshiko, et al.
Publicado: (2018)

Plasma metabolomic profiling reveals factors associated with dose-adjusted trough concentration of tacrolimus in liver transplant recipients
por: Zhu, Huaijun, et al.
Publicado: (2022)

Integrated proteomics and metabolomics analysis of transgenic and gene-stacked maize line seeds
por: Liu, Weixiao, et al.
Publicado: (2021)

Proteomic and Metabolomic Analysis of Bone Marrow and Plasma from Patients with Extramedullary Multiple Myeloma Identifies Distinct Protein and Metabolite Signatures
por: Dunphy, Katie, et al.
Publicado: (2023)

Plasma proteome and metabolome characterization of an experimental human thyrotoxicosis model
por: Pietzner, Maik, et al.
Publicado: (2017)

A plasma metabolomic signature discloses human breast cancer
por: Jové, Mariona, et al.
Publicado: (2017)

A metabolomic signature of decelerated physiological aging in human plasma
por: Janssens, Georges E., et al.
Publicado: (2023)

Plasma proteomic signatures predict dementia and cognitive impairment
por: Tanaka, Toshiko, et al.
Publicado: (2020)

Thermodynamic Signatures of Blood Plasma Proteome in Neurodegenerative Pathologies
por: Danailova, Avgustina, et al.
Publicado: (2023)

Proteomics reveals unique plasma signatures in constitutional thinness
por: Cominetti, Ornella, et al.
Publicado: (2022)

Integrative metabolomic and proteomic signatures define clinical outcomes in severe COVID-19
por: Buyukozkan, Mustafa, et al.
Publicado: (2022)

PiggyBac-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report
por: Li, Chenggong, et al.
Publicado: (2021)

Combined Signature of the Fecal Microbiome and Plasma Metabolome in Patients with Ulcerative Colitis
por: Sun, Meiling, et al.
Publicado: (2019)

Metabolomic signature of amino acids in plasma of patients with non-segmental Vitiligo
por: Marzabani, Rezvan, et al.
Publicado: (2021)

Plasma metabolomic signatures of dual decline in memory and gait in older adults
por: Tian, Qu, et al.
Publicado: (2023)

Plasma metabolomic analysis of human hepatocellular carcinoma: Diagnostic and therapeutic study
por: Chen, Yang, et al.
Publicado: (2016)

A Plasma Proteomic Signature of Skeletal Muscle Mitochondrial Function
por: Zampino, Marta, et al.
Publicado: (2020)

PLASMA PROTEOMIC SIGNATURE OF DECLINE IN GAIT SPEED AND GRIP STRENGTH
por: Liu, Xiaojuan, et al.
Publicado: (2022)

Plasma proteomic signature of decline in gait speed and grip strength
por: Liu, Xiaojuan, et al.
Publicado: (2022)

38 Plasma proteomic signature of motoric cognitive risk syndrome
por: Gomez, Gabriela T., et al.
Publicado: (2023)

Methods to capture proteomic and metabolomic signatures from cerebrospinal fluid and serum of healthy individuals
por: Lilley, Laura M., et al.
Publicado: (2022)

T-ALL Cells as Tool Cells for CAR T Therapy
por: Ren, Anqi, et al.
Publicado: (2023)

This CAR won’t start: predicting nonresponse in ALL
por: Webster, Jonathan A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8kdm559tftftmv6ppq2er2m4ju